HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

cefodizime

RN given refers to (6R-(6alpha,7beta(Z)))-isomer

Also Known As:

HR 221; HR-221; Hoechst brand of cefodizime disodium; Modivid; cefodizime disodium; cefodizime, dipotassium salt, (6R-(6alpha,7beta(Z)))-isomer; cefodizime, disodium salt, (6R-(6alpha,7beta(Z)))-isomer

Networked: 97 relevant articles (15 outcomes, 17 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Tanaka, Masatoshi: 2 articles (01/2009 - 03/2002)
2.	Muratani, Tetsuro: 2 articles (06/2006 - 04/2006)
3.	Matsumoto, Tetsuro: 2 articles (06/2006 - 04/2006)
4.	Shimokawa, Hiroshi: 2 articles (06/2006 - 04/2006)
5.	Sato, Yumiko: 2 articles (06/2006 - 04/2006)
6.	Yokoo, Daisuke: 2 articles (06/2006 - 04/2006)
7.	Ikuyama, Toshihiro: 2 articles (06/2006 - 04/2006)
8.	Ando, Yukiko: 2 articles (06/2006 - 04/2006)
9.	Yanai, Shigeaki: 2 articles (06/2006 - 04/2006)
10.	Takahashi, Koichi: 2 articles (06/2006 - 04/2006)

Related Diseases

1.	Infection 02/01/1997 - "Based on the data obtained with this model, once-daily dosing with 1 g cefodizime (i.v.) should be effective against infections due to the commonest Gram-negative bacteria (E. " 07/01/1984 - "The protective effects of HR 221 on experimental infections in mice caused by Staphylococcus aureus Smith, Escherichia coli C-11, Proteus vulgaris GN-76 and Serratia marcescens No. 2 were directly related to its in vitro activity against these strains. " 06/01/1989 - "In this study, cefodizime (CDZM, THR-221) was administered to 34 children with infections and the efficacy was evaluated in 30 patients. " 06/01/1989 - "Clinical trials of cefodizime (CDZM, THR-221) were carried out in pediatric infection. " 06/01/1989 - "[Clinical and pharmacokinetic study on cefodizime, a new cephalosporin antibiotic, in the pediatric infections]."
2.	Respiratory Tract Infections (Respiratory Tract Infection) 11/01/1990 - "An open multicentre study of the efficacy and tolerance of cefodizime 1 g bd intravenously or intramuscularly in lower respiratory tract infections." 05/01/1997 - "Cefodizime once daily in the treatment of lower respiratory tract infections." 03/01/1997 - "Cefodizime given in single or divided doses for the treatment of lower respiratory tract infection." 02/01/1994 - "Cefodizime inhibited many of the important respiratory pathogens and can be suggested as an active antimicrobial agent for respiratory tract infections." 11/01/1990 - "It was concluded that cefodizime should be a useful agent in the therapy of respiratory tract infections."
3.	Urinary Tract Infections (Urinary Tract Infection) 03/01/1991 - "A randomized, dose comparison study of cefodizime in the treatment of lower urinary tract infections in women." 08/01/1989 - "In the urinary tract infection group, T1/2(beta) and AUC in the kidneys (infected site) and liver that mainly participate in elimination of cefodizime considerably increased differently from the control group. " 03/01/1991 - "In a prospective randomized study, the efficacy and safety of 1 and 2 g of cefodizime administered as single intramuscular injections were compared in a total of 50 women having either complicated or uncomplicated lower urinary tract infections (LUTI). " 11/01/1990 - "The clinical efficacy of cefodizime has been tested in several open and comparative studies, above all in lower respiratory tract infections (LRTI) and uncomplicated urinary tract infections (UTI), performed in 151 centres in Europe, Latin America, South-Eastern Asia and South Africa. " 11/01/1992 - "A single dose of cefodizime 1 or 2 g is also useful in treating lower urinary tract infections, particularly uncomplicated infections, with a rate of clinical success of 72 to 88%. "
4.	Pneumonia (Pneumonitis) 05/01/1995 - "Single daily dose of cefodizime in patients with community-acquired pneumonia: an open-label, controlled, randomized study. " 05/01/1995 - "We conclude that cefodizime 1 g IM once daily is an effective dosing regimen in the treatment of patients with community-acquired pneumonia." 05/01/1995 - "The objective of this study was to compare the clinical and bacteriologic efficacy and safety of cefodizime 1 g intramuscularly (IM) once daily (group A) versus cefodizime 1 g IM twice daily (group B) and versus ceftriaxone 1 g IM once daily (group C) in patients with community-acquired pneumonia. " 12/01/1984 - "In the treatment of experimental Klebsiella pneumonia, cefodizime was superior to cefotaxime and cefuroxime. " 06/01/1989 - "Cefodizime (CDZM, THR-221) was given intravenously to 20 children with the following acute bacterial infections: 2 cases each of tonsillitis, bronchitis, purulent cervical lymphadenitis, and urinary tract infections and 12 cases of pneumonia. "
5.	Cholecystitis 01/01/1998 - "The results of the clinical and laboratory study of the efficacy of the prophylactic and therapeutic use of cefodizime (modivid) in patients with chronic calculous cholecystitis and burns are presented. "

Related Drugs and Biologics

1.	cefodizime
2.	Cefotaxime (Kendrick)
3.	Ceftriaxone (Ceftriaxon)
4.	Spectinomycin (Spectinomycin Hydrochloride)
5.	Ceftizoxime (Cefizox)
6.	Minocycline (Cyclops)
7.	Azithromycin (Zithromax)
8.	Norfloxacin
9.	Ciprofloxacin (Cipro)
10.	Cefuroxime (Zinacef)

Related Therapies and Procedures

1.	Injections
2.	Intramuscular Injections
3.	Renal Dialysis (Hemodialysis)
4.	Aftercare (After-Treatment)
5.	Intravenous Injections